July 2024 - Cancer Currents Blog
-
FDA Approves HPV Tests That Allow for Self-Collection in a Health Care SettingThe expanded approval of two HPV tests allows the patient to collect a vaginal sample themselves in a health care setting, rather than a health provider collecting a sample during a pelvic exam. The availability of a self-collection option in health care settings could help widen access to cervical cancer screening.
-
Treating the Whole Person: How Cancer Centers Are Addressing Social NeedsWhile treating people’s health-related social needs has always been a part of health care in one form or other, cancer centers and community cancer clinics increasingly are viewing the people they treat through a social lens and addressing social needs—including transportation, food, and housing—as part of patient care.
-
Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain MetastasesLorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with ALK-positive advanced non-small cell lung cancer, according to new clinical trial results. Treatment with lorlatinib also helped prevent new brain metastases.
-
Trial Establishes Preferred Treatment for Some People with Esophageal CancerFor people with locally advanced esophageal cancer, a chemotherapy regimen called FLOT is the preferred treatment, according to results from a large clinical trial. People treated with FLOT lived much longer than those treated with the CROSS regimen.
-
Program Helps Medically Underserved, Minority Cancer Survivors Be More ActiveA program in Texas helped minority and medically underserved cancer survivors get much more physical activity, according to a new study. Participants also reported improved physical functioning and quality of life.
-
Tumor Signatures May Help Explain Global Differences in Kidney Cancer RatesBy analyzing patterns of DNA mutations in kidney cancers from people around the world, researchers have discovered new clues about possible causes of the disease. Identifying these mutational signatures might lead to strategies for preventing kidney cancer.